Vascular Solutions Inc. announced Friday a deal to be acquired by Teleflex Inc. in a deal valued at $1 billion.
Under terms of the deal, Teleflex will pay $56 in cash for each Vascular share outstanding, a 1.6% premium to Thursday’s closing price of $55.10, which matched Wednesday’s record close.
The acquisition, which is expected to close in the first half of 2017, will be funded through the proceeds from one or more debt financings. Vascular’s stock, which was still inactive in premarket trade, has run up 60% year to date, while Teleflex shares have rallied 11% and the S&P 500 has gained 7.2%.
By Tom Kilgore
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.